Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ORIC vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VOR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–1 Matrix Metrics)

VOR Overall Winner 6-Pillar Tally: ORIC 1 – 4 VOR (1 Tie) Matrix Metrics: ORIC 1 – 5 VOR

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Oric Pharmaceuticals, Inc. (ORIC) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ORIC carries a Unified Composite Score of 46.2/100 (HOLD) at $7.68 (N/M Forward P/E, 0.0% operating margin), whereas VOR carries 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ORIC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ORIC vs VOR
ORIC NASDAQ
Oric Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$7.68
-2.23% 1D
Market Cap $881.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.33β · 129% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.6%), weak momentum, RSI 30
RSI-14: 30.3 · SMA20: $9.82 · SMA50: $11.45
VOR NASDAQ Head-to-Head Winner
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.91β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87

6-Pillar Scorecard Institutional Category Breakdown (ORIC 1 – 4 VOR)

Columns: Metric · ORIC · VOR
1. Valuation Multiples VOR
Forward P/E N/M N/M
Trailing P/E N/M 0.1x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale VOR
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $881.0M $1.2B
3. Profitability & Quality ORIC
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -39.8% -125.4%
4. Balance Sheet & Cash Flow VOR
Cash Generation (TTM) -$112M -$1.63B
Cash Flow Margin N/A N/A
Net Cash / Leverage $34M Net Cash $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 588.5% (77th %ile) 127.0% (6th %ile)
Put/Call OI Skew N/A 2.03x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ORIC (1) vs VOR (5)
Institutional Metric ORIC VOR Criterion Row Edge
Market Capitalization
Scale
$881.0M $1.2B Larger Scale VOR
Trailing P/E Ratio
Valuation
N/M 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-39.8% -125.4% Higher ROE ORIC
52-Week Range Position
Momentum
6% ($7–$15) 65% ($6–$26) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
1.33β · 129% Vol 1.91β · 61% Vol Lower Realized Risk VOR
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 57.8 / 100 (HOLD) Higher Composite VOR
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$112M ($34M Net Cash) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +44.59 pp
ORIC: -37.77% · VOR: +6.82%
3M Horizon VOR +27.52 pp
ORIC: -44.79% · VOR: -17.27%
6M Horizon VOR +39.4 pp
ORIC: -3.09% · VOR: +36.31%
1Y Horizon VOR +134.5 pp
ORIC: -36.96% · VOR: +97.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ORIC vs VOR. Trailing 12-month operating profitability (ORIC 0.0% vs VOR 0.0%) and valuation multiples (ORIC N/M vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ORIC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-39.8% · N/M
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ORIC BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 588.5%
IV Percentile 77th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ORIC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 127.0%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ORIC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $881.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ORIC vs VOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Oric Pharmaceuticals, Inc. (ORIC) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ORIC carries a Unified Composite Score of 46.2/100 (HOLD) at $7.68 (N/M Forward P/E, 0.0% operating margin), whereas VOR carries 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ORIC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VOR leads the Growth & Scale pillar: ORIC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ORIC generates N/A in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, ORIC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

VOR screens cheaper on headline valuation multiples. ORIC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ORIC (-39.8% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ORIC carries 588.5% implied volatility (77th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.33β · 129% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.